European Growth
Opportunity

Over the last four years, Avextra has built one of the only vertically integrated EU operations from genetic selection and cultivation to sales and distribution. By effectively and responsibly deploying capital, we’ve built valuable assets strategically across Europe and are already present in some of the biggest EU markets.

Meet Avextra: Europe’s leader in Cannabis-based medicine


Assets strategically developed across Europe

Country access
via high calibre partners

Avextra license/
infrastructure

Cultivation

Production

Our Vision: To understand and harness the therapeutic potential of the cannabis plant and thereby improve the quality of life for patients around the world.

Avextra controls the entire value chain

From genetic selection through to product innovation

Genetic Selection and Cultivation

Product Development and R&D

Production and Manufacturing

Distribution

Clinical Pipeline

GENETIC SELECTION aND CULTIVaTION

We have a 600m2 purpose-built cultivation facility on 250ha of land in Portugal to cultivate rare genetics for indication-based formulations.

Check out our state- of-the-art medical cannabis cultivation facility in Portugal in this behind-the-scenes.

PRODUCT DEVELOPMENT
aND R&D

Focused development of novel extract-based product innovations

PRODUCTION aND MaNUFaCTURING

In a 10,000m2 state-of-the-art GMP manufacturing facility in Germany and a highly qualified team with 75 years of experience in botanical extraction of plant-based medicines.

DISTRIBUTION

Our products are already present in 4 of the biggest EU markets with expansion plans in place. We have one of the largest sales team in Germany, equipped with exceptional connections.

Here you see some placeholder text to explain the picture.

CLINICaL PIPELINE

Clinical Program in place to gather product-specific data for future commercials, with 3 clinical programs starting in 2023.

We invest a third of our total budget in Research & Development

Press Releases

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…

Germany unveils scaled-down recreational cannabis legalization plan

Germany unveils scaled-down recreational cannabis legalization plan

Today marked a historic day in Germany as major strides were made in removing the stigma surrounding this plant. Martha Lurther, CSO at Avextra shares her thoughts on Germany’s plans.…

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…

Strategic
Partnerships

We are always looking to connect with those who share our vision. If you’re interested in receiving a detailed deck and discovering how you can be part of our success, please contact us today.

CONTaCT US:

EN